CY1106691T1 - Πρωτεϊνη του καψιδιου ιου/χιμαιρες υποδοχεα και μεθοδοι χρησης - Google Patents

Πρωτεϊνη του καψιδιου ιου/χιμαιρες υποδοχεα και μεθοδοι χρησης

Info

Publication number
CY1106691T1
CY1106691T1 CY20071100870T CY071100870T CY1106691T1 CY 1106691 T1 CY1106691 T1 CY 1106691T1 CY 20071100870 T CY20071100870 T CY 20071100870T CY 071100870 T CY071100870 T CY 071100870T CY 1106691 T1 CY1106691 T1 CY 1106691T1
Authority
CY
Cyprus
Prior art keywords
receptor
virus
capsido
protein
methods
Prior art date
Application number
CY20071100870T
Other languages
English (en)
Inventor
Anthony Louis Devico
Timothy R. Fouts
Robert G. Tuskan
Original Assignee
University Of Maryland Biotechnology Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Maryland Biotechnology Institute filed Critical University Of Maryland Biotechnology Institute
Publication of CY1106691T1 publication Critical patent/CY1106691T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η εφεύρεση αφορά σε χιμαιρικά μόρια που περιέχουν μία αλληλουχία καψιδίου ιού και μία αλληλουχία υποδοχέα που μπορούν να αλληλεπιδρούν μεταξύ τους για να σχηματίσουν ένα σύμπλεγμα που είναι ικανό να προσδένεται με ένα συν-υποδοχέα. Τέτοιου τύπου χιμαιρικά μόρια επομένως παρουσιάζουν λειτουργικές ιδιότητες χαρακτηριστικές ενός συμπλέγματος υποδοχέα-πρωτεΐνης καψιδίου και είναι χρήσιμα ως παράγοντες που αναστέλλουν την μόλυνση από τον ιό σε κύτταρα λόγω της κατάληψης του συν-υποδοχέα που είναι παρών πάνω στο κύτταρο, για παράδειγμα. Σε ιδιαίτερες εκδοχές, το χιμαιρικό πολυπεπτίδιο περιλαμβάνει ένα πολυπεπτίδιο του περιβλήματος ενός ιού ανοσοανεπάρκειας, όπως οι ΗIV, SIV, FIV FeLV, ΡFΡ και ο ιός του έρπητα. Οι κατάλληλες αλληλουχίες υποδοχέα για χρήση σε ένα χιμαιρικό πολυπεπτίδιο περιλαμβάνουν για παράδειγμα, τις αλληλουχίες CCR5 και CΧCR4.
CY20071100870T 1999-10-08 2007-07-02 Πρωτεϊνη του καψιδιου ιου/χιμαιρες υποδοχεα και μεθοδοι χρησης CY1106691T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15832199P 1999-10-08 1999-10-08
PCT/US2000/027546 WO2001027294A1 (en) 1999-10-08 2000-10-06 Virus coat protein/receptor chimeras and methods of use

Publications (1)

Publication Number Publication Date
CY1106691T1 true CY1106691T1 (el) 2012-05-23

Family

ID=22567583

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100870T CY1106691T1 (el) 1999-10-08 2007-07-02 Πρωτεϊνη του καψιδιου ιου/χιμαιρες υποδοχεα και μεθοδοι χρησης

Country Status (9)

Country Link
EP (1) EP1137786B1 (el)
AT (1) ATE358726T1 (el)
AU (1) AU7862500A (el)
CY (1) CY1106691T1 (el)
DE (1) DE60034211T2 (el)
DK (1) DK1137786T3 (el)
ES (1) ES2284532T3 (el)
PT (1) PT1137786E (el)
WO (1) WO2001027294A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076636A1 (en) * 1993-05-07 2004-04-22 Ranajit Pal HIV immunogenic complexes
US6908612B2 (en) * 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US7811580B2 (en) 2002-05-07 2010-10-12 Novartis Vaccines & Diagnostics, Inc. Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes
WO2004073603A2 (en) * 2003-02-14 2004-09-02 Aeras Global Tuberculosis Vaccine Foundation Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity
CA2719522A1 (en) * 2007-03-26 2008-10-02 University Of Maryland, Baltimore A non-destructive method to quantify and isolate antigen-specific b cells and uses thereof
WO2014055413A2 (en) * 2012-10-02 2014-04-10 Bloodcenter Research Foundation A method of providing cellular therapy using modified natural killer cells or t lymphocytes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT89484B (pt) * 1988-01-22 1994-03-31 Gen Hospital Corp Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
EP0550516A1 (en) * 1990-09-28 1993-07-14 Hospital For Joint Diseases Method for inhibiting the infectivity of human immunodeficiency virus
DE69328726D1 (de) * 1992-02-10 2000-06-29 Univ Durham Verwendung synthetischer peptide zur induktion der toleranz gegen t- und b-zell epitope von autoantigenen
ATE207760T1 (de) * 1993-05-07 2001-11-15 Akzo Nobel Nv Hiv immunogene komplexe
AU7127798A (en) * 1997-04-18 1998-11-13 President And Fellows Of Harvard College Bifunctional polypeptides for cell-specific viral targeting

Also Published As

Publication number Publication date
DK1137786T3 (da) 2007-08-06
DE60034211D1 (de) 2007-05-16
PT1137786E (pt) 2007-07-13
EP1137786A1 (en) 2001-10-04
ES2284532T3 (es) 2007-11-16
WO2001027294A1 (en) 2001-04-19
DE60034211T2 (de) 2007-12-20
WO2001027294A9 (en) 2002-05-16
AU7862500A (en) 2001-04-23
EP1137786B1 (en) 2007-04-04
ATE358726T1 (de) 2007-04-15

Similar Documents

Publication Publication Date Title
CY1106691T1 (el) Πρωτεϊνη του καψιδιου ιου/χιμαιρες υποδοχεα και μεθοδοι χρησης
Denner Immunosuppression by retroviruses: implications for xenotransplantation
Wyatt et al. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens
ATE120234T1 (de) Hiv-3-retrovirus und seine verwendung.
WO2003016333A3 (en) Virus coat protein/receptor chimeras and methods of use
RU2017133854A (ru) Вектор
KR910004207A (ko) 치료기능을 가진 알부민 유도체
CY1107760T1 (el) Κυτταρα φακοϊικου εγκλεισμου
TR200100163T2 (tr) Güçlendirilmiş farmakokinetik özelliklere sahip hibrid polipeptidler
IL86278A (en) Endowing cells with antibody specificity using chimeric t cell receptor
DE69535125D1 (de) Impstoff gegen felines immunodefizienz-virus
DE68927665T2 (de) Von synthetischer DNS abgeleitete rekombinante HIV-1-Antigene
ATE380822T1 (de) Funf-helix protein
EP2055780A3 (en) Antigen constructs useful in the detection and differentiation of antibodies to HIV
DK0975783T3 (da) Retrovirusvektorer, fremgangsmåde til fremstilling heraf samt deres anvendelse til genoverføring til CD4-positive celler
Pancio et al. Human immunodeficiency virus type 2 Vpx-Gag interaction
NO983375L (no) Retroviral vektor og anvendelse derav i genterapi
Chen et al. HIV-2 transmembrane protein gp36 binds to the putative cellular receptor proteins P45 and P62
WO2007024976A3 (en) Virus coat protein/receptor chimeras and methods of use
ATE417108T1 (de) Hiv-2 und siv-1 nukleotidsequenzen
ATE437176T1 (de) Gereinigtes hüllprotein eines retrovirus, dafür kodierende nukleinsäuren, vektoren und deren verwendung
Marques HIV-1 Rev C-terminal domain is important for Rev function restriction in murine A9 cells (Immune deficiency)
Wachinger et al. The p17 stretch at the N terminus of the HIV1-gag precursor and the intracellular part of HIV1-env gp41 have heptad repeat regions in their sequences that could bind to each other in a coiled coil
Schaefer Functional characterization of the interaction between Nef and the T cell receptor zeta chain (Immune deficiency)
Worthylake Structural studies of HIV-1 Gag proteins (Immune deficiency)